ClinicalTrials.gg
RecruitingNCT05688774PROGRESSCOMORBUpdated Mar 13, 2024

Study of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression

An observational study in Pneumonia, Sepsis and Shock, Septic, sponsored by Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps. Recruiting at 10 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps · Observational

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Pneumonia with a site in Germany — 8 open to participants now, 10 under way, 4 of them phase 3. Pneumonia · Germany.

Planned enrollment
10th of 21
300 · median 130
Started
2022
with 3 others
Observational
21 of 49
3 open now
Registered
41st of 49
by date
Lead sponsor
2 of 49
Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps

Among the 49 studies in Pneumonia with a site in Germany, this one is the 10th largest by planned enrollment of the 21 observational ones that give a count, is one of 4 that started in 2022, is one of 21 observational ones, and was the 41st registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

8 of the 49 studies in Pneumonia with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Pneumonia with a site in Germany, or all of them as a file.
02

Study summary

Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization. However, the course of disease of patients in the hospital remains hard to predict. While most patients will recover quickly, some will, despite appropriate treatment, develop a severe course leading to sepsis and systemic responses resulting in organ dysfunction. The PROGRESS consortium aims to identify clinical, genetic, and other molecular markers and combinations there of predicting a severe course of pneumonia in the hospital. Such predictors will, for instance, support decisions on earlier transfer of patients to intensive care and thus improving outcome. PROGRESS-COMORB aims to extend findings from the previous PROGRESS study to patients with more severe preexisting conditions and immunosuppression.

Read the detailed description

Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization. However, the course of disease of patients in the hospital remains hard to predict. While most patients recover quickly, others will, despite appropriate treatment, develop a severe course leading to sepsis and systemic responses resulting in organ dysfunction. The PROGRESS consortium aims to identify clinical, genetic and other molecular markers and combinations there of predicting a severe course of pneumonia in the hospital. Such predictors will, for instance, support decisions on earlier transfer of patients to intensive care and thus improving outcome. PROGRESS-COMORB aims to extend findings from the previous PROGRESS study to patients with more severe preexisting conditions and immunosuppression.

In this observational, longitudinal case-cohort study, patients are enrolled within 48 hours of hospitalization (within 7 days for patients directly admitted to intensive care) and patient's progress is followed in much detail for up to six days thereafter. Further data are collected until discharge from the hospital. Patients are followed up on at days 28, 180, and 360 after enrollment.

Baseline assessment comprises sociodemographic, anamnestic, family history, and life-style information. Upon enrollment, Pneumonia Severity Index (PSI) and CURB-65 are determined. For the day of enrollment, up to six subsequent study days routine laboratory and clinical observations and information on therapy are documented as well as data for determining the Sequential Organ Failure Assessment (SOFA) score, Systemic Inflammatory Response Syndrome (SIRS) status, and organ dysfunction. Starting with enrollment, up to four consecutive sets of biomaterials are collected comprising serum, plasma, and materials for extraction of RNA. Blood for extraction of DNA is collected once.

Follow up comprises vital status, housing situation, recurrence of pneumonia, stroke, myocardial infarction, occurrence of diabetes and a quality of life questionnaire.

In the PROGRESS consortium, the transition (progression) from uncomplicated community-acquired pneumonia acquired pneumonia (uCAP) to severe CAP (sCAP) to CAP with severe sepsis or septic shock or multiple organ failure (ssCAP) is investigated. Previous work of the PROGRESS consortium led to the successful identification of an operationalization for the severity of CAP and causal pathomechanistic correlations, a clinical prognosis score, the assignment of altered molecules to dysfunctions of the respiratory tract, kidneys, coagulation, cardiovascular system, and liver, and a gene expression signature for early detection of patients at risk of developing ssCAP.

For the translation of findings from the PROGRESS-CAP study into clinical applicability, their applicability to CAP patients with immunosuppression or with more severe preexisting conditions has to be confirmed.

03

Conditions studied

  • Pneumonia
  • Sepsis
  • Shock, Septic

Keywords

  • community ascquired pneumonia
  • CAP
  • disease progression
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients hospitalized for treatment of community acquired pneumonia. Patients can be enrolled in general care, intensive care, and in emergency departments.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hospitalization with community acquired pneumonia (CAP) confirmed by pulmonary infiltrate in chest imaging
  2. Valid form
  3. Working diagnosis of CAP by enrolling physician
  4. No hospitalization for any reason within 28 days prior to hospitalization for the current episode of CAP
  5. At least 2 out of the five following clinical symptoms:

    • Fever
    • Cough
    • Purulent sputum
    • Shortness of breath or need for respiratory support
    • Crackling or rales on auscultation, dullness to percussion, or bronchial breathing
  6. At least 1 of the following criteria

    • Known infection or AIDS
    • Anti-tumor treatment within the past six months
    • Therapy with ≥ 20mg for ≥ 14 days before enrollment
    • Non-steroidal therapy within the past six months
    • Cytostatic therapy within the past six months
    • Radiation therapy within the past six months
    • Bone marrow transplant received
    • Respiratory support at home via tracheostoma
    • Cystic fibrosis
    • Heart failure: (NYHA) Stadium IV or HFrEF (defined as \<40%).
    • Decompensated liver disease ( class C)
    • Diabetes mellitus with ≥ 8,5 %
    • End-stage renal disease requiring dialysis
    • Pulmonary hypertension (all classes) with mPAP > 20 mmHg (right heart catheter)

Exclusion criteria

Exclusion Criteria:

  1. Participation in this study at an earlier time
  2. More than 48 hours in the hospital before enrollment (for patients directly to intensive care: more than 7 days)
  3. Pregnancy
  4. Breastfeeding
  5. Active tuberculosis
  6. Acute lung injury or acute respiratory distress syndrome for extrapulmonary reasons
  7. Massive aspiration
  8. Sepsis with extrapulmonary focus
  9. Acute pulmonary embolism
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Worst measure of disease severity

    Disease severity is operationalized by the Sequential Organ Failure Assessment (SOFA-score).

    Time frame: Between enrollment and day six

Secondary outcomes

  1. All cause mortality

    Time frame: up to one year after enrollment

  2. disease-specific mortality

    Time frame: up to one year after enrollment

  3. duration of hospitalization

    Time frame: up to one year after enrollment

  4. duration of intensive care treatment

    Time frame: up to one year after enrollment

  5. duration of ventilator assisted breathing

    Time frame: up to one year after enrollment

07

Study locations

9 of 10 sites recruiting
  • Charité - Universitätsmedizin Berlin, Medizinische Klinik m. S. Infektiologie und Pneumologie
    Berlin, 13353, Germany
    Recruiting
  • Humboldt-Klinikum Vivantes, Kardiologie und kons. Intensivmedizin
    Berlin, 13509, Germany
    Recruiting
  • Gemeinschaftskrankenhaus Havelhöhe, Kardio-Pneumologie
    Berlin, 14089, Germany
    Recruiting
  • Städtisches Klinikum Dessau, Innere Medizin
    Dessau, 06847, Germany
    Recruiting
  • Universitätsklinikum Hamburg Eppendorf, Onkologisches Zentrum, Pneumologische Studienzentrale
    Hamburg, 20246, Germany
    Recruiting
  • Universitätsklinikum Leipzig, Klinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie
    Leipzig, 04103, Germany
    Recruiting
  • Klinikum St. Georg gGmbH, Klinik für Infektions-/Tropenmedizin und Nephrologie
    Leipzig, 04129, Germany
    Recruiting
  • Universitätsklinikum Gießen und Marburg, Klinik für Pneumologie und Anästhesie
    Marburg, 35043, Germany
    Recruiting
  • Universitätsklinikum Münster, Kardiologie 1
    Münster, 48149, Germany
    Recruiting
  • Diakoniekrankenhaus Rotenburg(Wümme)gGmbH, Zentrum für Pneumologie
    Rotenburg, 27356, Germany
    Withdrawn

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data will be made available after conclusion of the study. Participants can apply for clinical and molecular study data by sending structured project proposals to the PROGRESS board. The PROGRESS board will evaluate proposals for scientific quality, adherence to the limits set by patient's informed consent statements and by intellectual property regulations of the funding agency. Proposals shall not be denied without concrete reason.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.

Of 210 non-industry observational studies under Pneumonia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 60 months is above that.

Counting every sponsor, half of 223 studies reached it within 27 months; a quarter within 13 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2023
First posted
Jan 18, 2023
StartActual
Feb 28, 2022
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2028
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05688774
Lead sponsor
Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps
Collaborators
Charite University, Berlin, Germany, University of Leipzig, Jena University Hospital
Responsible party
Sponsor
First posted
Jan 18, 2023
Start date
Feb 28, 2022
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Mar 13, 2024

Study contacts

Sarah Berger, MD
Contact
sarah.berger@charite.de
+49-30-450553347
Peter Ahnert, MD
Contact
peter.ahnert@imise.uni-leipzig.de
+49-341-9716282
Norbert Suttorp, MD
principal investigator · Charité Univerity, Berlin, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion